Year-over-year earnings per share growth for the last twelve months: Innate Pharma S.A. (IPHA)

The growth potential of Innate Pharma S.A. (IPHA) is driven by low market saturation of targeted antibodies and the expansion of its licensing base. On GURU.Markets, current quarterly EPS dynamics confirm this trend, where the value 8.90 represents the current figure. Growth is fueled by payments from pharma behemoths for the success of the ANKET platform, while the business model relies on the activation of NK cells to combat tumors.

Innate Pharma S.A. (IPHA) monetizes unique antibodies through royalties and partnerships with pharma behemoths. The quarterly dynamics of net income per share illustrate the efficiency of this intellectual property. This indicator transforms discrete reporting data into a continuous trend, eliminating information gaps between releases. The rising curve confirms the market value of the patents, although buying at local highs increases the risk of capital freeze. The upward vector indicates business scaling.